Physicians Care Plaza, LLC

Physicians Care Plaza, LLC was paid $429K by Medicaid between Jan 2018 and Aug 2018, across 31 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 22% of everything it billed.

33Billing provider infoPHYSICIANS CARE PLAZA, LLC
GULFPORT, MS 39503

33aNPI1316137300assigned 07/26/2007

33bProvider typeFamily Medicine Physician

28Total paid$429K

24GClaims14,835

24DCodes billed31

24AFirst – last monthJan 2018 – Aug 2018

Compared with peers

Next to other Family Medicine Physician providers in Mississippi

Rank by total paid#62 of 306

Median peer was paid$59K

This provider vs. median7.2×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	14,835	$429K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	22%	2,726	2,393	$94K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	17%	504	410	$73K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	13%	1,993	1,619	$58K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	8.4%	411	290	$36K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	5.5%	356	281	$24K
99203	Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity	5.2%	376	312	$22K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	3.9%	718	655	$17K
20553		3.8%	840	639	$16K
93923		3.4%	396	137	$15K
94727		2.9%	396	376	$13K
94729		2.6%	396	376	$11K
95923		2.2%	201	157	$10K

19 more codes

94060		2.1%	399	$9K
94618		1.8%	435	$8K
95924		1.5%	181	$6K
94200		<1%	397	$4K
72110		<1%	167	$3K
L0637	Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panels, posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panels, produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise	<1%	14	$3K
72070		<1%	189	$3K
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	88	$866.56
72050		<1%	30	$715.74
73560		<1%	25	$446.58
93040		<1%	174	$444.55
97163		<1%	12	$402.40
72114		<1%	18	$300.12
J3490	Unclassified drugs	<1%	552	$181.90
J2001	Injection, lidocaine hcl for intravenous infusion, 10 mg	<1%	790	$1.67
97010		0%	35	$0.00
98941	Chiropractic manipulative treatment; spinal, 3-4 regions	0%	281	$0.00
J3300	Injection, triamcinolone acetonide, preservative free, 1 mg	0%	1,339	$0.00
94375		0%	396	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialHOUSEL, BILLIE (CREDENTIALING SPECIALIST)